The pharmaceutical sector led the rise, the strength can continue for how long?

　　Pharmaceutical Network Pharmaceutical Stock Market, investment side, in the A-share major theme industries, the pharmaceutical sector led the rise, the income is quite rich According to the data, the Shenwan Biopharmaceutical Index rose 13.24% between February 3 and April 22 From the internal segmentof of the sector, the performance is differentiated, among which medical deviceperformance was bright, up 34.56 percent, chemical raw materials, biological products, up 21.30 percent, 19.92 percent, respectively, while medical services, Chinese medicine performance is poor, up and down 5.46 percent, -0.40 percent, chemicals and pharmaceutical business performance, rose 8.13 percent, 6.55 percent, respectively
But at the same time as the market rose, the valuation of the plate also rose How long will the strength of the pharmaceutical sector last? There are many sub-sectors in the pharmaceutical sector, and will there be differences in the driving logic and trend of each segment? Analysts pointed out that the state pays more attention to the pharmaceutical industry, and promotes the industry to enter the stage of high-quality, short-term development In addition, based on the properties of the pharmaceutical sector itself, in the context of consumption upgrading, scientific and technological innovation and the deepening degree of aging of the population, the comparative advantage of the industry is outstanding, the business climate is still in the rising channel
The pharmaceutical sector includes many sub-sectors, although the overall plate has the "long cow" attribute, but different sub-sectors, the same sub-industry of different companies performance differences are obvious For investors, the pharmaceutical industry has a high professional barriers, the choice of stock is not easy, it is better to borrow the medical theme fund, by professional asset management institutions for their own capture of the pharmaceutical sector investment opportunities Suggest investors do not chase up and down, choose a good fund, slowly become rich is a better investment secret
It is reported that the pharmaceutical sector since the beginning of 2019 all the way up, has recently returned to more than five years of relative highs Data show that as of April 22, 2020, the pharmaceutical sector price-earnings ratio of 54.81, the ten-year average of 39.40, the sector valuation or has reached a relatively high "The current valuation is at a reasonable high, but the performance and business climate of the pharmaceutical industry are still on the rise," the researchers said The industry believes that the pharmaceutical industry has 30 years to go ahead The logic is that the population will continue to grow and the average life expectancy of this generation will be at least longer than it is now At the same time, the standard of living of this generation will be higher and higher Moreover, in terms of income, the income of everyone will not be less in the next 30 years than it is now, and the expenditure on medical care will increase exponentially "We judge that pharmaceutical companies that operate around these three diseases will grow 100-500 times in the future Investment in the pharmaceutical industry, the core still want to seize three diseases: diabetes, cardiovascular, hypertension Now all three diseases can be controlled and cured, the current market also has to prevent the above three diseases brought complications products Grasp the main contradictions, already can earn 70% of the profits of the pharmaceutical consumption industry In addition, pharmaceutical biology is the big direction, is now very hot, but it is worth noting that the valuation is high, the risk is greater
In addition, some people pointed out that the pharmaceutical sector configuration more attention to the future long-term main line of the pharmaceutical field, the current policy emphasizes complementing the short board of public health, while continuing to promote the collection, increase the promotion of localization and innovative drug support, it is expected that the domestic is expected to focus on the combination of medical prevention, graded diagnosis and treatment, emergency mechanism, Internet medical and other directions to promote the reform of the medical system Therefore, the long-term logic, can continue to pay attention to the biomedical theme fund allocation value.